{
    "symbol": "ANIP",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-09 10:26:10",
    "content": " Cost of sales excluding depreciation and amortization increased by $8.5 million to $32.9 million in the third quarter of 2021 compared to $24.4 million in the prior year period primarily due to increased sales volumes of generic products, including $6.5 million of costs related to Novitium products during the current year period with no comparable sales activity in the prior year and an increase of $1.7 million related to increased sales of product subjects to profit sharing arrangements. Research and development expenses were $7.7 million in the third quarter of 2022 an increase of $5.2 million from the prior year period, primarily due to expenses related to Novitium generic research and development activities during the current year with no comparable expenses in the prior year, coupled with in process research and development charges of $1.2 million recognized in the current year period in conjunction with purchase accounting for our ANDA acquisition from Oakrum Pharma, LLC."
}